Anavex Life Sciences Corp (AVXL)

[F1ash]

Anavex’s drug was purchased under the stewardship of someone who formed a biotech company with little to no apparent biotech experience. It was purchased for a paltry sum of money after lying dormant on the shelf for much of it’s patent life. It’s publicized MOA is Sigma1 activation. Sigma1 activation is not “cutting edge”, lots of other drugs activate Sigma1, many even have a much higher affinity than A2-73. Anavex was in dire straits financially before DrM was brought onboard.

IMHO, investors should be thanking their lucky stars for DrM. Almost 30 million in the bank, trials underway, and a market cap of 1/4 billion dollars on the thinnest of hopes from a long shot drug with an extremely questionable pedigree. Where would Anavex be without DrM?